419 related articles for article (PubMed ID: 33099710)
1. Validity of the EQ-5D-5L questionnaire among the general population of Poland.
Młyńczak K; Golicki D
Qual Life Res; 2021 Mar; 30(3):817-829. PubMed ID: 33099710
[TBL] [Abstract][Full Text] [Related]
2. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
Jankowska A; Młyńczak K; Golicki D
Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
[TBL] [Abstract][Full Text] [Related]
3. Psychometric properties comparison between EQ-5D-5L and EQ-5D-3L in the general Thai population.
Kangwanrattanakul K; Parmontree P
Qual Life Res; 2020 Dec; 29(12):3407-3417. PubMed ID: 32780315
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Yfantopoulos J; Chantzaras A; Kontodimas S
Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
[TBL] [Abstract][Full Text] [Related]
5. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
[TBL] [Abstract][Full Text] [Related]
6. Psychometric performance assessment of Malay and Malaysian English version of EQ-5D-5L in the Malaysian population.
Shafie AA; Vasan Thakumar A; Lim CJ; Luo N
Qual Life Res; 2019 Jan; 28(1):153-162. PubMed ID: 30317426
[TBL] [Abstract][Full Text] [Related]
7. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
8. Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
Rencz F; Lakatos PL; Gulácsi L; Brodszky V; Kürti Z; Lovas S; Banai J; Herszényi L; Cserni T; Molnár T; Péntek M; Palatka K
Qual Life Res; 2019 Jan; 28(1):141-152. PubMed ID: 30225788
[TBL] [Abstract][Full Text] [Related]
9. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
Kim SH; Kim HJ; Lee SI; Jo MW
Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B.
Jia YX; Cui FQ; Li L; Zhang DL; Zhang GM; Wang FZ; Gong XH; Zheng H; Wu ZH; Miao N; Sun XJ; Zhang L; Lv JJ; Yang F
Qual Life Res; 2014 Oct; 23(8):2355-63. PubMed ID: 24627090
[TBL] [Abstract][Full Text] [Related]
11. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients.
Pattanaphesaj J; Thavorncharoensap M
Health Qual Life Outcomes; 2015 Feb; 13():14. PubMed ID: 25890017
[TBL] [Abstract][Full Text] [Related]
12. Comparing the psychometric properties of EQ-5D-3L and EQ-5D-5L proxy ratings by informal caregivers and a health professional for people with dementia.
Michalowsky B; Hoffmann W; Mohr W; Rädke A; Xie F
Health Qual Life Outcomes; 2022 Oct; 20(1):140. PubMed ID: 36199138
[TBL] [Abstract][Full Text] [Related]
13. Psychometric Properties of EQ-5D-3L and EQ-5D-5L in Cognitively Impaired Patients Living with Dementia.
Michalowsky B; Hoffmann W; Xie F
J Alzheimers Dis; 2021; 83(1):77-87. PubMed ID: 34275901
[TBL] [Abstract][Full Text] [Related]
14. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases.
Scalone L; Ciampichini R; Fagiuoli S; Gardini I; Fusco F; Gaeta L; Del Prete A; Cesana G; Mantovani LG
Qual Life Res; 2013 Sep; 22(7):1707-16. PubMed ID: 23192232
[TBL] [Abstract][Full Text] [Related]
15. Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China.
Jiang J; Hong Y; Zhang T; Yang Z; Lin T; Liang Z; Lu P; Liu L; Wang B; Xu Y; Luo N
Qual Life Res; 2021 Jul; 30(7):2045-2060. PubMed ID: 33821418
[TBL] [Abstract][Full Text] [Related]
16. Validity of EQ-5D-5L in stroke.
Golicki D; Niewada M; Buczek J; Karlińska A; Kobayashi A; Janssen MF; Pickard AS
Qual Life Res; 2015 Apr; 24(4):845-50. PubMed ID: 25347978
[TBL] [Abstract][Full Text] [Related]
17. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the three-level and the five-level versions of the EQ-5D.
Christiansen ASJ; Møller MLS; Kronborg C; Haugan KJ; Køber L; Højberg S; Brandes A; Graff C; Diederichsen SZ; Nielsen JB; Krieger D; Holst AG; Svendsen JH
Eur J Health Econ; 2021 Jun; 22(4):621-628. PubMed ID: 33733344
[TBL] [Abstract][Full Text] [Related]
19. Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece.
Yfantopoulos JN; Chantzaras AE
Eur J Health Econ; 2017 May; 18(4):519-531. PubMed ID: 27262480
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Psychometric Properties of the EQ-5D-3L-Y and EQ-5D-5L-Y Instruments in Spanish Children and Adolescents.
Pérez-Sousa MÁ; Olivares PR; Ramírez-Vélez R; Gusi N
Value Health; 2021 Dec; 24(12):1799-1806. PubMed ID: 34838278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
